Why These 15 Stocks Are Skyrocketing in 2025

Page 12 of 14

3. Guardant Health (NASDAQ:GH)

Number of Hedge Fund Holders In Q3 2024: 28

Guardant Health (NASDAQ:GH) is an oncology company that makes blood and tissue tests for cancer.

The stock is up significantly in 2025 due to its announcement that its revenue for all of 2024 was $737 million, up 31%. Q4 revenue also reached $200 million. Test volumes have increased in both its clinical and biopharma segments.

Moreover, Guardant Health has obtained Medicare coverage for its minimal residual disease (MRD) test. Plus, it launched a blood test for colorectal cancer.

The average analyst price target for the stock is $44, implying 6.8% downside.

GH stock is up 48.6% year-to-date.

Page 12 of 14